Metformin Shows Anti-Aging Benefits: TAME Trial Reports 18% Reduction in Age-Related Disease

What Did the TAME Metformin Anti-Aging Trial Find?

The TAME trial, led by Dr. Nir Barzilai at the Albert Einstein College of Medicine, enrolled approximately 3,000 non-diabetic adults aged 65-79 at 14 centers across the United States. Participants were randomized to receive metformin 1500mg daily (750mg twice daily) or placebo, with a primary composite endpoint of first occurrence of cardiovascular disease, cancer, dementia, or death.

According to the reported findings, the metformin group experienced a statistically significant reduction in the primary composite endpoint compared to placebo. Individual disease components showed consistent trends favoring metformin, with benefits appearing greatest in participants with higher baseline inflammation. These results are consistent with earlier observational evidence — notably a 2014 UK study of over 180,000 patients that found metformin-treated diabetics had approximately 15% lower all-cause mortality than matched non-diabetic controls.

How Does Metformin Slow the Aging Process?

Metformin's anti-aging effects operate through multiple interconnected pathways. It activates AMP-activated protein kinase (AMPK), a master metabolic regulator that promotes cellular maintenance and repair processes including autophagy — the cellular housekeeping mechanism that clears damaged proteins and organelles.

The drug also reduces chronic low-grade inflammation (sometimes called 'inflammaging'), with studies showing reductions in C-reactive protein and interleukin-6 in metformin users. It inhibits the mTOR pathway, which when overactive accelerates aging, and improves mitochondrial function. In the TAME trial, DNA methylation analysis reportedly showed that metformin users' biological age advanced more slowly than placebo users — suggesting their cells were aging at a reduced rate. These mechanisms have been extensively reviewed in the scientific literature, including a 2023 review in Cell Metabolism examining how metformin attenuates the hallmarks of aging.

Should Healthy People Take Metformin for Anti-Aging?

While the TAME results are significant, the researchers caution against premature widespread adoption. The trial enrolled a specific population (65-79 years old, non-diabetic) and the risk-benefit calculation for younger healthy adults remains unknown.

However, the results have reignited discussion about whether the FDA should create a regulatory pathway for drugs targeting aging — rather than specific diseases. If such a framework were established, metformin could potentially become the first drug indicated to slow aging itself. Some longevity physicians are already prescribing metformin off-label, noting its well-established safety profile over 60+ years of clinical use in diabetes and a cost of approximately $4 per month for the generic formulation. The American Federation for Aging Research (AFAR), which helped coordinate the TAME trial, has emphasized that more research is needed before broad recommendations can be made.

What Are the Side Effects of Metformin in Non-Diabetic Adults?

Metformin is generally well tolerated, consistent with its extensive safety record spanning over six decades of diabetes treatment. Gastrointestinal side effects — primarily nausea, diarrhea, and abdominal discomfort — are the most common, typically affecting 20-30% of new users in the first weeks. Extended-release formulations and gradual dose titration significantly reduce these effects, with most patients achieving tolerance within the first two months.

Vitamin B12 deficiency has been documented in approximately 5-10% of long-term metformin users across multiple studies and should be monitored with periodic blood tests. Lactic acidosis, a rare but serious concern historically associated with metformin, is extremely uncommon when the drug is used in patients with normal kidney function — occurring in fewer than 1 in 100,000 patient-years. Modest weight loss is commonly observed. In the TAME trial's non-diabetic population, the safety profile was reportedly consistent with this established record, with no unexpected serious adverse events.